Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + abacavir + ritonavir + atazanavir
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a four-drug antiretroviral combination regimen consisting of lamivudine, abacavir, ritonavir, and atazanavir. It is used in the treatment of HIV-1 infection. Lamivudine and abacavir are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by acting as chain terminators during viral DNA synthesis. Atazanavir is a protease inhibitor that blocks the activity of the HIV protease enzyme, preventing viral protein processing and maturation; its effectiveness is enhanced when boosted with low-dose ritonavir, which inhibits CYP3A-mediated metabolism to increase atazanavir plasma levels[1][8]. This combination has been shown to be effective and well-tolerated in ART-naïve patients over 48 weeks[1]. The regimen targets multiple steps in the HIV replication cycle for durable viral suppression.
- Brand names
- ReyatazNorvirZiagenEpivirEpzicomKivexa
- Other names
- ATV/r + ABC/3TCATV + RTV + ABC + 3TCatazanavir + ritonavir + abacavir + lamivudine-Juan A. Arnaiz-HIV infection
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)
Beyond the preview
Go deeper on lamivudine + abacavir + ritonavir + atazanavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + abacavir + ritonavir + atazanavir.